Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1996 Mar 15;314(Pt 3):969–976. doi: 10.1042/bj3140969

Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.

M Hatanaka 1, T Seya 1, M Matsumoto 1, T Hara 1, M Nonaka 1, N Inoue 1, J Takeda 1, A Shimizu 1
PMCID: PMC1217151  PMID: 8615796

Abstract

We have investigated the mechanisms of defects in the glycosyl-phosphatidylinositol (GPI)-anchored complement regulatory proteins delay-accelerating factor (DAF) and/or CD59 in a panel of human leukaemia cell lines that lack surface expression of these proteins: U937 (DAF+/CD59-), CEM (DAF-/CD59+), TALL (DAF-/CD59-) and a substrain of Ramos [Ramos(-)] (DAF-/CD59-). Northern blotting and reverse transcription-PCR revealed that the main cause of the DAF and/or CD59 deficiency is the failure of mRNA expression in most of the cell lines, except in Ramos(-) in which sufficient mRNA for DAF and CD59 was produced. U937, CEM and TALL cells were not defective in GPI anchor formation as assessed by the detection of other GPI-anchored proteins. No gene abnormality corresponding to DAF or CD59 was detected by Southern blotting. Thus the cause of the defects of DAF and/or CD59 in these leukaemia cell lines except for Ramos(-) is virtually undetectable steady-state levels of the relevant mRNA, most likely attributable to lack of transcription in these cell lines. On the other hand, Ramos(-) cells failed to generate a GPI anchor, whereas they normally expressed DAF and CD59 transcripts. The transfection of phosphatidylinositol-glycan class A (PIG-A) cDNA into Ramos(-) cells restored DAF and CD59 expression, indicating that the defective mechanism in GPI anchor formation is similar to that in paroxysmal noctural haemoglobinuria (PNH) cells, i.e. a deficiency of the PIG-A gene product. Thus the mechanisms of the defects of DAF and/or CD59 in human leukaemia cell lines are not uniform, and in most cases are different from that proposed to cause PNH.

Full Text

The Full Text of this article is available as a PDF (435.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryant R. W., Granzow C. A., Siegel M. I., Egan R. W., Billah M. M. Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells. J Immunol. 1990 Jan 15;144(2):593–598. [PubMed] [Google Scholar]
  2. Bryant R. W., Granzow C. A., Siegel M. I., Egan R. W., Billah M. M. Wheat germ agglutinin and other selected lectins increase synthesis of decay-accelerating factor in human endothelial cells. J Immunol. 1991 Sep 15;147(6):1856–1862. [PubMed] [Google Scholar]
  3. Chu G., Hayakawa H., Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res. 1987 Feb 11;15(3):1311–1326. doi: 10.1093/nar/15.3.1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davitz M. A., Low M. G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986 May 1;163(5):1150–1161. doi: 10.1084/jem.163.5.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Devine D. V., Gluck W. L., Rosse W. F., Weinberg J. B. Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone. J Clin Invest. 1987 Jan;79(1):314–317. doi: 10.1172/JCI112802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fukuda H., Seya T., Hara T., Matsumoto M., Kinoshita T., Masaoka T. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma. Immunol Lett. 1991 Aug;29(3):205–209. doi: 10.1016/0165-2478(91)90171-6. [DOI] [PubMed] [Google Scholar]
  8. Hara T., Kojima A., Fukuda H., Masaoka T., Fukumori Y., Matsumoto M., Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol. 1992 Oct;82(2):368–373. doi: 10.1111/j.1365-2141.1992.tb06431.x. [DOI] [PubMed] [Google Scholar]
  9. Hatanaka M., Inai S., Matsumoto M., Miyagawa S., Masaoka T., Kanamaru A., Kawakita M., Yonemura Y., Sugita Y., Seya T. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Clin Immunol Immunopathol. 1993 Oct;69(1):52–59. doi: 10.1006/clin.1993.1149. [DOI] [PubMed] [Google Scholar]
  10. Holguin M. H., Fredrick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989 Jul;84(1):7–17. doi: 10.1172/JCI114172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hyman R. Somatic genetic analysis of the expression of cell surface molecules. Trends Genet. 1988 Jan;4(1):5–8. doi: 10.1016/0168-9525(88)90120-5. [DOI] [PubMed] [Google Scholar]
  12. Kinoshita T., Medof M. E., Silber R., Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1985 Jul 1;162(1):75–92. doi: 10.1084/jem.162.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kuraya M., Minarovits J., Okada H., Klein E. HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines. Immunol Lett. 1993 Jul;37(1):35–39. doi: 10.1016/0165-2478(93)90129-p. [DOI] [PubMed] [Google Scholar]
  14. Lachmann P. J. Protection against complement lysis. Biochem Soc Trans. 1990 Dec;18(6):1159–1160. doi: 10.1042/bst0181159. [DOI] [PubMed] [Google Scholar]
  15. Mahoney J. F., Urakaze M., Hall S., DeGasperi R., Chang H. M., Sugiyama E., Warren C. D., Borowitz M., Nicholson-Weller A., Rosse W. F. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood. 1992 Mar 15;79(6):1400–1403. [PubMed] [Google Scholar]
  16. Medof M. E., Lublin D. M., Holers V. M., Ayers D. J., Getty R. R., Leykam J. F., Atkinson J. P., Tykocinski M. L. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2007–2011. doi: 10.1073/pnas.84.7.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miyata T., Takeda J., Iida Y., Yamada N., Inoue N., Takahashi M., Maeda K., Kitani T., Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993 Feb 26;259(5099):1318–1320. doi: 10.1126/science.7680492. [DOI] [PubMed] [Google Scholar]
  18. Miyata T., Yamada N., Iida Y., Nishimura J., Takeda J., Kitani T., Kinoshita T. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994 Jan 27;330(4):249–255. doi: 10.1056/NEJM199401273300404. [DOI] [PubMed] [Google Scholar]
  19. Morgan B. P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989 Nov 15;264(1):1–14. doi: 10.1042/bj2640001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  21. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  22. Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430–5434. doi: 10.1073/pnas.80.17.5430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Philbrick W. M., Palfree R. G., Maher S. E., Bridgett M. M., Sirlin S., Bothwell A. L. The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur J Immunol. 1990 Jan;20(1):87–92. doi: 10.1002/eji.1830200113. [DOI] [PubMed] [Google Scholar]
  24. Rosse W. F. Dr Ham's test revisited. Blood. 1991 Aug 1;78(3):547–550. [PubMed] [Google Scholar]
  25. Rotoli B., Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Baillieres Clin Haematol. 1989 Jan;2(1):113–138. doi: 10.1016/s0950-3536(89)80010-1. [DOI] [PubMed] [Google Scholar]
  26. Seya T., Farries T., Nickells M., Atkinson J. P. Additional forms of human decay-accelerating factor (DAF). J Immunol. 1987 Aug 15;139(4):1260–1267. [PubMed] [Google Scholar]
  27. Seya T., Hara T., Matsumoto M., Akedo H. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol. 1990 Jul 1;145(1):238–245. [PubMed] [Google Scholar]
  28. Seya T., Hara T., Okada M., Kojima A., Matsumoto M., Akedo H. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them. Int Immunol. 1992 Dec;4(12):1361–1371. doi: 10.1093/intimm/4.12.1361. [DOI] [PubMed] [Google Scholar]
  29. Seya T., Tejima H., Fukuda H., Hara T., Matsumoto M., Hatanaka M., Sugita Y., Masaoka T. Acute promyelocytic leukemia with CD59 deficiency. Leuk Res. 1993 Oct;17(10):895–896. doi: 10.1016/0145-2126(93)90155-e. [DOI] [PubMed] [Google Scholar]
  30. Shibata T., Cosio F. G., Birmingham D. J. Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J Immunol. 1991 Dec 1;147(11):3901–3908. [PubMed] [Google Scholar]
  31. Shichishima T., Terasawa T., Hashimoto C., Ohto H., Takahashi M., Shibata A., Maruyama Y. Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria. Blood. 1993 Apr 1;81(7):1855–1862. [PubMed] [Google Scholar]
  32. Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988 Oct;104(4):633–637. doi: 10.1093/oxfordjournals.jbchem.a122524. [DOI] [PubMed] [Google Scholar]
  33. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., Arai N. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 1988 Jan;8(1):466–472. doi: 10.1128/mcb.8.1.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993 May 21;73(4):703–711. doi: 10.1016/0092-8674(93)90250-t. [DOI] [PubMed] [Google Scholar]
  35. Telen M. J., Hall S. E., Green A. M., Moulds J. J., Rosse W. F. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med. 1988 Jun 1;167(6):1993–1998. doi: 10.1084/jem.167.6.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thomas D. J., Lublin D. M. Identification of 5'-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression. J Immunol. 1993 Jan 1;150(1):151–160. [PubMed] [Google Scholar]
  37. Tsuji S., Kaji K., Nagasawa S. Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface. J Immunol. 1994 Feb 1;152(3):1404–1410. [PubMed] [Google Scholar]
  38. Williams T. M., Burlein J. E., Ogden S., Kricka L. J., Kant J. A. Advantages of firefly luciferase as a reporter gene: application to the interleukin-2 gene promoter. Anal Biochem. 1989 Jan;176(1):28–32. doi: 10.1016/0003-2697(89)90267-4. [DOI] [PubMed] [Google Scholar]
  39. Yamashina M., Ueda E., Kinoshita T., Takami T., Ojima A., Ono H., Tanaka H., Kondo N., Orii T., Okada N. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990 Oct 25;323(17):1184–1189. doi: 10.1056/NEJM199010253231707. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES